FDA Puts MDMA for PTSD on Hold: No More Psychedelics?

In a move that surprised many in the mental health and psychedelic communities, the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Lykos Therapeutics, halting the approval of MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD). The FDA is calling for additional clinical trials to further evaluate the safety and efficacy of the treatment, delaying what could have been a significant moment in psychedelic-assisted psychotherapy.

The FDA’s Decision: More Data Required

The FDA’s CRL highlights the agency’s request for another Phase 3 clinical trial before approving MDMA for PTSD. This additional trial will focus on gathering long-term safety and efficacy data. While previous studies showed promising results, the FDA expressed concerns about potential risks, suggesting the evidence provided so far was not sufficient for approval.

This decision is a setback for advocates and researchers who have spent years pushing for the approval of MDMA-AT. Rick Doblin, PhD, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), expressed disappointment but remains committed to advancing the therapy. Lykos Therapeutics has also indicated that it will work to meet the FDA’s requirements by either providing new data or addressing concerns with existing literature.

MDMA: A Promising Yet Controversial Treatment

MDMA, commonly known as ecstasy, has shown promise in treating PTSD. The therapy combines MDMA with psychotherapy, helping patients confront and process traumatic memories. Studies suggest that MDMA-AT could provide lasting relief for PTSD sufferers, many of whom do not respond to conventional treatments like selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy (CBT).

Key Studies on MDMA and PTSD

Research spearheaded by MAPS includes several clinical trials that demonstrate MDMA’s potential in treating PTSD. In a 2018 Phase 2 trial published in The Lancet Psychiatry, 54% of participants no longer met the criteria for PTSD after receiving MDMA-AT, compared to just 23% in the placebo group.

A more recent Phase 3 trial (2019-2021) published in Nature Medicine showed that 67% of participants undergoing MDMA therapy no longer had PTSD by the trial’s end, compared to 32% in the placebo group. These results have made MDMA-AT one of the most promising treatments for PTSD, with long-term benefits sustained for up to 12 months post-treatment.

What Are the Risks the FDA Is Concerned About?

While MDMA shows potential, the FDA has expressed concerns regarding several risks:

• Neurotoxicity: There are concerns about possible long-term effects on brain health, particularly serotonin depletion, which is a known risk in recreational MDMA use.
• Cardiovascular Risk: MDMA can raise heart rate and blood pressure, creating potential dangers for individuals with cardiovascular conditions.
• Addiction Potential: MDMA has a high potential for abuse, raising concerns about dependency in a therapeutic setting.
• Emotional Vulnerability: While MDMA enhances emotional openness, it may also leave patients more susceptible to emotional distress, underscoring the need for highly trained therapists.

What Additional Data Does the FDA Require?

The FDA’s call for further trials is primarily focused on:

• Long-Term Safety: The FDA wants more data on potential neurotoxicity and other long-term effects of MDMA, particularly in therapeutic settings.
• Diverse Populations: Larger trials that include diverse patient populations with varying degrees of PTSD severity and comorbidities are needed.
• Optimal Dosing: The FDA is exploring whether lower doses or different treatment intervals might reduce risks while maintaining therapeutic benefits.
• Therapist Training: The FDA seeks standardized guidelines on therapist training, session protocols, and handling adverse emotional reactions.

How Do MDMA Trials Compare to Other Psychedelics?

MDMA is not the only psychedelic under study for mental health disorders. Other compounds, like psilocybin, LSD, and DMT, are also being tested for conditions such as depression and anxiety. Here’s how MDMA trials compare:

• Psilocybin: Psilocybin has shown strong results in treating treatment-resistant depression and anxiety, with response rates similar to MDMA. Unlike MDMA, which focuses on trauma processing, psilocybin often induces mystical experiences to shift patient perspectives.
• LSD: LSD is being studied for anxiety and depression, especially in terminally ill patients. Its longer duration (8-12 hours) can complicate therapy logistics compared to MDMA (3-5 hours), but early results are promising.
• DMT: DMT provides intense, short-duration experiences that are being explored for treating depression and trauma-related disorders. It’s seen as a promising alternative due to its short duration, which simplifies therapy logistics.

MDMA’s primary strength lies in its ability to help patients process trauma in real time, whereas psilocybin and LSD focus more on altering consciousness to facilitate healing.

Industry Reactions: Hope and Setbacks

The FDA’s decision has sparked reactions from researchers and companies involved in psychedelic therapies. Numinus Wellness, a company focused on psychedelic-assisted therapy, expressed disappointment but remains committed to advancing research. Cybin and MindMed continue pushing forward with their own trials for psilocybin and LSD, respectively, as they explore treatments for depression and anxiety.

What’s Next for MDMA-Assisted Therapy?

While the FDA’s decision delays MDMA’s approval, it is not the end of the road. Lykos Therapeutics and MAPS plan to address the FDA’s concerns and submit new data. Researchers remain optimistic that MDMA-AT will eventually meet the FDA’s requirements and gain approval.

In the meantime, other psychedelic therapies continue to progress, with psilocybin, DMT, and LSD showing potential across multiple mental health disorders. For PTSD patients, MDMA remains a promising option, though it may take more time before the treatment becomes widely available.

Conclusion

The FDA’s decision to delay MDMA-AT for PTSD reflects its commitment to ensuring the highest standards of safety and efficacy. While this delay is a setback, it underscores the importance of thorough research in introducing powerful psychedelic therapies to the market. With additional trials and data, MDMA may still become a critical tool in treating PTSD and other trauma-related conditions.

FDA Puts MDMA for PTSD on Hold – Resources:

1. The Lancet Psychiatry: MDMA-assisted psychotherapy for PTSD: a randomized, double-blind, placebo-controlled Phase 2 trial (2018)
2. Nature Medicine: Phase 3 trial of MDMA-assisted therapy for PTSD (2021)
3. Multidisciplinary Association for Psychedelic Studies (MAPS): Research and advocacy on MDMA-assisted therapy for PTSD
4. FDA Complete Response Letter: Overview of the CRL issued to Lykos Therapeutics
5. Psychiatric Times: MDMA on hold: What’s next for psychedelics?
6. NBC News: FDA’s stance on MDMA-assisted therapy for PTSD

Related